BCBS Massachusetts weight loss drug spend jumps 250%: 5 notes

Blue Cross and Blue Shield of Massachusetts reported a $114 million operating loss in the first nine months of the year, partly due to skyrocketing claims for GLP-1 medications.

Advertisement

Five notes:

1. BCBSMA reported an after-tax third quarter net income of $29.2 million on revenue of $2.4 billion (1.21% net margin). 

2. Year-to-date, BCBSMA reported an after-tax net income of $27.1 million on revenue of $7.2 billion (0.38% net margin). 

3. The company’s operating loss in the third quarter was $19.8 million. Compared to a year ago, Q3 operating income is down $145 million and net income is down $135.1 million.

4. 2,000 members are starting GLP-1 medications every month, and spending on GLP-1s has risen by 250% since last year, putting the company on track to spend nearly $200 million on the medications in 2024.

5. “We continue to see a significant escalation in spending on medical and pharmacy services; in fact, the growth in spending is the highest in at least a decade,” CFO Ruby Kam said. “While the increase in spending is across almost all categories of services, the growth in spending on new and popular GLP-1 weight loss medications is worth noting.”

Advertisement

Next Up in Payer

Advertisement

Comments are closed.